Bangladesh · Delayed Price · Currency is BDT Pharma Aids Statistics
Total Valuation
Pharma Aids has a market cap or net worth of BDT 1.58 billion. The enterprise value is 1.53 billion.
| Market Cap | 1.58B |
| Enterprise Value | 1.53B |
Important Dates
The next estimated earnings date is Wednesday, November 18, 2026.
| Earnings Date | Nov 18, 2026 |
| Ex-Dividend Date | Nov 26, 2026 |
Share Statistics
Pharma Aids has 3.12 million shares outstanding. The number of shares has decreased by -0.02% in one year.
| Current Share Class | 3.12M |
| Shares Outstanding | 3.12M |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 18.78% |
| Owned by Institutions (%) | n/a |
| Float | 2.53M |
Valuation Ratios
The trailing PE ratio is 18.02.
| PE Ratio | 18.02 |
| Forward PE | n/a |
| PS Ratio | 3.11 |
| PB Ratio | 3.10 |
| P/TBV Ratio | 3.10 |
| P/FCF Ratio | 28.07 |
| P/OCF Ratio | 20.58 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.58, with an EV/FCF ratio of 27.29.
| EV / Earnings | 17.53 |
| EV / Sales | 3.02 |
| EV / EBITDA | 12.58 |
| EV / EBIT | 13.79 |
| EV / FCF | 27.29 |
Financial Position
The company has a current ratio of 3.00, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.00 |
| Quick Ratio | 1.60 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.12 |
| Debt / FCF | 0.25 |
| Interest Coverage | 44.36 |
Financial Efficiency
Return on equity (ROE) is 18.58% and return on invested capital (ROIC) is 19.19%.
| Return on Equity (ROE) | 18.58% |
| Return on Assets (ROA) | 11.06% |
| Return on Invested Capital (ROIC) | 19.19% |
| Return on Capital Employed (ROCE) | 20.73% |
| Weighted Average Cost of Capital (WACC) | 5.25% |
| Revenue Per Employee | 5.40M |
| Profits Per Employee | 931,021 |
| Employee Count | 94 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 4.88 |
Taxes
In the past 12 months, Pharma Aids has paid 21.66 million in taxes.
| Income Tax | 21.66M |
| Effective Tax Rate | 19.84% |
Stock Price Statistics
The stock price has increased by +1.94% in the last 52 weeks. The beta is 0.17, so Pharma Aids's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +1.94% |
| 50-Day Moving Average | 546.62 |
| 200-Day Moving Average | 562.48 |
| Relative Strength Index (RSI) | 34.33 |
| Average Volume (20 Days) | 10,982 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharma Aids had revenue of BDT 507.39 million and earned 87.52 million in profits. Earnings per share was 28.05.
| Revenue | 507.39M |
| Gross Profit | 161.93M |
| Operating Income | 111.27M |
| Pretax Income | 109.17M |
| Net Income | 87.52M |
| EBITDA | 121.95M |
| EBIT | 111.27M |
| Earnings Per Share (EPS) | 28.05 |
Balance Sheet
The company has 57.78 million in cash and 14.33 million in debt, with a net cash position of 43.45 million or 13.93 per share.
| Cash & Cash Equivalents | 57.78M |
| Total Debt | 14.33M |
| Net Cash | 43.45M |
| Net Cash Per Share | 13.93 |
| Equity (Book Value) | 509.54M |
| Book Value Per Share | 163.31 |
| Working Capital | 279.47M |
Cash Flow
In the last 12 months, operating cash flow was 76.64 million and capital expenditures -20.44 million, giving a free cash flow of 56.20 million.
| Operating Cash Flow | 76.64M |
| Capital Expenditures | -20.44M |
| Depreciation & Amortization | 10.68M |
| Net Borrowing | n/a |
| Free Cash Flow | 56.20M |
| FCF Per Share | 18.01 |
Margins
Gross margin is 31.91%, with operating and profit margins of 21.93% and 17.25%.
| Gross Margin | 31.91% |
| Operating Margin | 21.93% |
| Pretax Margin | 21.52% |
| Profit Margin | 17.25% |
| EBITDA Margin | 24.03% |
| EBIT Margin | 21.93% |
| FCF Margin | 11.08% |
Dividends & Yields
This stock pays an annual dividend of 3.00, which amounts to a dividend yield of 0.59%.
| Dividend Per Share | 3.00 |
| Dividend Yield | 0.59% |
| Dividend Growth (YoY) | 16.67% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 11.07% |
| FCF Payout Ratio | 162.09% |
| Buyback Yield | 0.02% |
| Shareholder Yield | 0.61% |
| Earnings Yield | 5.55% |
| FCF Yield | 3.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on December 4, 2011. It was a forward split with a ratio of 10.
| Last Split Date | Dec 4, 2011 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |